Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
Provided By GlobeNewswire
Last update: Aug 4, 2025
$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023
VYJUVEK approved in Japan for the treatment of DEB patients from birth
Read more at globenewswire.com
